Sign In
Buy TRVN
$0.0010
+0 (+0%)
At Close: Jun 03, 2026
Why Merrimack Pharmaceuticals Shares Jumped Around 213%; Here Are 114 Biggest Movers From Yesterday
10:12am, Thursday, 10'th Nov 2022 Benzinga
Gainers
Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) shares climbed 212.8% to close at $12.51 on Wednesday after partner Ipsen reported Onivyde met its primary and key secondary endpoint. Merrimac
Trevena (TRVN) Reports Q3 Loss, Misses Revenue Estimates
01:25pm, Wednesday, 09'th Nov 2022 Zacks Investment Research
Trevena (TRVN) delivered earnings and revenue surprises of 0% and 203.06%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Trevena Announces Completion of Phase 1 Study for TRV045, Novel S1P Receptor Modulator
12:02pm, Wednesday, 09'th Nov 2022 GlobeNewswire Inc.
TRV045 demonstrated a favorable tolerability profile with no reported SAEs and no lymphopenia
Trevena (TRVN) Reports Q3 Loss, Misses Revenue Estimates
09:47am, Wednesday, 09'th Nov 2022
Trevena (TRVN) delivered earnings and revenue surprises of 0% and 203.06%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Trevena to Release Third Quarter 2022 Financial Results on November 9, 2022
07:00am, Monday, 07'th Nov 2022
Company to host a Conference Call & Webcast at 8:00 a.m. ET Company to host a Conference Call & Webcast at 8:00 a.m. ET
Trevena Announces OLINVYK Poster Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting
11:00am, Monday, 24'th Oct 2022 GlobeNewswire Inc.
OLINVYK study demonstrated a statistically significant reduced impact on respiratory function compared to IV morphine, among elderly/overweight subjects
Trevena to Participate at the H.C. Wainwright Annual Global Investment Conference
07:00am, Wednesday, 07'th Sep 2022
CHESTERBROOK, Pa., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with cen
What Makes Trevena (TRVN) a New Buy Stock
04:00pm, Tuesday, 16'th Aug 2022 Zacks Investment Research
Trevena (TRVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What Makes Trevena (TRVN) a New Buy Stock
01:33pm, Tuesday, 16'th Aug 2022
Trevena (TRVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Trevena, Inc's (TRVN) CEO Carrie Bourdow on Q2 2022 Results - Earnings Call Transcript
10:23pm, Friday, 12'th Aug 2022
Trevena, Inc. (NASDAQ:TRVN ) Q2 2022 Earnings Conference Call August 11, 2022 8:00 AM ET Company Participants Barry Shin – Chief Financial Officer Carrie Bourdow – President and Chief Executive Of
Trevena (TRVN) Reports Q2 Loss, Lags Revenue Estimates
12:25pm, Thursday, 11'th Aug 2022 Zacks Investment Research
Trevena (TRVN) delivered earnings and revenue surprises of 18.18% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Trevena (TRVN) Reports Q2 Loss, Lags Revenue Estimates
09:47am, Thursday, 11'th Aug 2022
Trevena (TRVN) delivered earnings and revenue surprises of 18.18% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Beat Estimates
10:15pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 6% and 15.41%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Trevena to Release Second Quarter 2022 Financial Results on August 11, 2022
07:00am, Monday, 08'th Aug 2022
Company to host a Conference Call & Webcast at 8:00 a.m. ET Company to host a Conference Call & Webcast at 8:00 a.m. ET
Eiger BioPharmaceuticals (EIGR) Reports Q2 Loss, Tops Revenue Estimates
11:25pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Eiger BioPharma (EIGR) delivered earnings and revenue surprises of 28.17% and 94.81%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
